Soft Mist Inhalers Market Size

Soft Mist Inhalers Market Size

Soft Mist Inhalers Market size was valued at USD 184.6 million in 2023 and is expected to grow at a CAGR of 9.2% from 2024 to 2032. Rising prevalence of respiratory conditions, growing emphasis on home-based healthcare, and increasing demand for drug delivery devices are among the key factors propelling the market progression.

To get key market trends

  Download Free Sample

The rising prevalence of respiratory conditions such as asthma, COPD, and bronchitis worldwide is a significant driving force for market expansion. These conditions necessitate efficient inhalation therapy, making soft mist inhalers among the preferred choice for patient treatment. For instance, as per the American Lung Association’s data, in 2022, 11.7 million people, or 4.6% of adults, reported a diagnosis of COPD (chronic obstructive pulmonary disease, chronic bronchitis, or emphysema) in the U.S. Additionally, according to statistics reported by the Centers for Disease Control and Prevention (CDC), the overall prevalence of asthma among adults stood at 8.0% in 2021.

Further, this increasing prevalence contributes to the growing demand for drug delivery devices such as soft mist inhalers, which in turn will fuel the industry growth. Furthermore, these devices play a vital role in ensuring the effective administration of medication, thereby improving patient outcomes and facilitating the advancement of personalized medicine approaches.

Soft mist inhalers (SMIs) are inhalation devices used to deliver medication directly into the lungs in the form of a slow-moving mist. Unlike traditional metered-dose inhalers (MDIs) or dry powder inhalers (DPIs), which deliver medication as aerosols or dry powders, soft mist inhalers produce a fine mist of medication that is propelled by mechanical energy.